Calquence (acalabrutinib) / AstraZeneca - LARVOL DELTA

Uncovering practice gaps in the management of mantle cell and diffuse large B-cell lymphomas amidst advances with Bruton's tyrosine kinase inhibitors (ASH 2025) - "Furthermore, only 36% of hematologists/oncologists reported confidence in using BTK inhibitors for newly diagnosed MCL—despite the recent frontline approval of acalabrutinib-based combinations—highlighting a critical gap in knowledge and comfort with modern therapeutic options... This multi-activity educational initiative successfully engaged clinicians who treat MCL and DLBCL, uncovering distinct challenges in clinical practice and highlighting persistent educational gaps. The findings affirm that while enthusiasm for integrating novel therapies exists, practical limitations such as lack of familiarity and barriers to access continue to hinder adoption. Given the evolving treatment landscape, particularly with the introduction of BTK inhibitors and other targeted agents in the frontline setting, continued clinician education is essential."

B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Cognitive Disorders • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Rare Diseases

Safety and efficacy of ibrutinib as a first line agent for Mantle Cell Lymphoma : A systematic review and meta-analysis (ASH 2025) - "While standard first-line chemotherapy regimens include rituximab and bendamustine or cytarabine containing regimens, Bruton tyrosine kinase inhibitors (BTKis), such as ibrutinib and zanubrutinib, have demonstrated efficacy in relapsed or refractory MCL and are now being explored as frontline options. Notably, acalabrutinib in combination with bedamustine and rituximab has received FDA approval for treatment-naïve MCL patients who are ineligible for autologous hematopoietic stem cell transplantation (HSCT)...Conclusions Ibrutinib-based regimens demonstrate a high objective response rate and an acceptable safety profile when used as a first-line treatment for MCL. However, the substantial heterogeneity and potential publication bias is identified."

Retrospective data • Review • Atrial Fibrillation • Bone Marrow Transplantation • Cardiovascular • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

National practice patterns and preferences in the use of fixed-duration vs. treat-to-progression therapies for CLL (ASH 2025) - "In the R/R setting, fixed-duration preferences included venetoclax plus rituximab (39%) and venetoclax plus obinutuzumab (34%)...Among TTP strategies, first-line use of acalabrutinib (56%) and zanubrutinib (52%) was prominent in the survey, aligning with claims data that showed both agents as the most prescribed TTP therapies (28% each)... This data highlighted evolving practice patterns in the management of CLL and revealed variation in treatment preferences among academic and community-based clinicians and between survey and claims data. While adoption of genetic testing and newer therapeutic options appears high, clinicians face ongoing challenges in selecting and implementing appropriate regimens, particularly when balancing patient-centered factors with clinical efficacy and operational realities. Both fixed-duration and TTP strategies offer distinct advantages and limitations."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53

Incidence of cardiac events associated with next-generation bruton tyrosine kinase (BTK) inhibitors compared to control in hematologic malignancies: A meta-analysis of randomized trials (ASH 2025) - "Most existing data are derived from studies of ibrutinib, the first generation BTKi which has known off-target receptor binding that may contribute to cardiotoxicity...Acalabrutinib was evaluated in four trials (ECHO, ELEVATE-TN, ASCEND, AMPLIFY), zanubrutinib in two (SEQUOIA, ROSEWOOD), and pirtobrutinib in one (BRUIN CLL-321)... This analysis of seven RCTs found that next-generation BTKi were associated with an elevated risk of atrial arrhythmias, particularly atrial fibrillation or flutter; however, the incidence of more severe cardiac events such as ventricular arrhythmias and myocardial infarction remains low and not significantly different between groups. The increased incidence of atrial rhythm disturbances may have important clinical implications, especially for patients with underlying cardiovascular risk. As use of these agents expands, clinicians should remain vigilant regarding potential cardiac effects and consider baseline evaluation and ongoing monitoring."

Retrospective data • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Myocardial Infarction • Oncology • Ventricular Tachycardia

Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy (ASH 2025) - P2 | "This retrospective, observational study examined the demographic and clinical characteristics, treatment patterns, reasons for treatment change, and treatment-limiting treatment-related adverse events (AEs) in patients with CLL/SLL who initiated zanubrutinib following an immediate switch from ibrutinib or acalabrutinib. Following the switch to zanubrutinib, recurrence of AEs was uncommon, and most patients stayed on treatment. These results support previously reported findings that zanubrutinib for CLL/SLL is well-tolerated despite prior BTKi therapy."

Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy (ASH 2025) - "In head-to-head trials, zanubrutinib was superior to ibrutinib (ALPINE trial; hazard ratio [HR]: 0.65; 95% confidence interval [CI]: 0.49-0.86), while acalabrutinib was noninferior to ibrutinib (ELEVATE-RR trial; HR: 1.00; 95% CI: 0.79-1.27) in patients with relapsed/refractory CLL. The primary reason for acalabrutinib discontinuation was toxicity. Consistent with previous research, real-world data from across the US have demonstrated that zanubrutinib was well tolerated and maintained effectiveness in patients with CLL who had received a prior BTK inhibitor."

Clinical • Real-world • Real-world evidence • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma

Improved survival in chronic lymphocytic leukemia over two decades: A SEER-based population analysis (2000–2021) (ASH 2025) - "Over the past twenty years, there has been a marked evolution in the landscape of treatment modalities, typified by the incorporation of chemoimmunotherapy in the early 2000s, followed by the advent of targeted therapeutic agents, including Bruton tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib) and BCL2 inhibitors (venetoclax) commencing in the year 2013. Among individuals diagnosed with Chronic Lymphocytic Leukemia (CLL) from the year 2000 to 2021, relative survival rates exhibited significant enhancement across all assessed temporal intervals: 1-year: 85.9% 2-year: 81.2% 5-year: 75.4% - Sex disparities: Female patients demonstrated a superior 5-year survival rate (77.3%) in comparison to their male counterparts (73.5%). - Age disparities: Patients below the age of 65 exhibited a 5-year survival rate exceeding 80%, Whereas patients aged 65 years and older experienced survival rates below 70% prior to the year 2010, yet this figure improved to over 74%..."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies (ASH 2025) - "This is an important consideration in clinical decision making where cardiovascular safety is a priority. Study findings should be interpretated within the context of the limitations including possible differential follow-up across studies, which may impact the incidence of AFib over time."

Clinical • Atrial Fibrillation • Cardiovascular • Hematological Malignancies • Oncology

Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States (ASH 2025) - "Treatment regimens were categorized into 7 mutually exclusive groups: bendamustine (B)-based chemotherapy, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without cytarabine), Bruton tyrosine kinase inhibitors (BTKi; covalent: zanubrutinib, acalabrutinib, ibrutinib, and non-covalent: pirtobrutinib), bortezomib (bort)-based, venetoclax (ven)-based, intensive chemotherapy (high-dose cytarabine, HyperCVAD (hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone, etc.), and other regimens (CAR-T or others). However, chemotherapy and/or immunotherapy were associated with the highest HCRU while BTKi were associated with the lowest HCRU. Notably, more than half of patients previously treated with BTKi and anti-CD20 therapies were subsequently treated with another covalent BTKi or a non-covalent BTKi, while approximately one-third received chemotherapy and/or immunotherapy, further emphasizing the need for novel..."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy (ASH 2025) - "First-Line Therapy Recommendations: CLL patients with del(17p)/TP53 mutations: For these high-risk patients, the panel strongly favoredcontinuous BTKi therapy, with second-generation BTKis (acalabrutinib, zanubrutinib) preferred due to their more favorable safety profiles...IGHV-unmutated CLL patients without del(17p)/TP53 mutations: While the majority of experts considered patient fitness for this group, recommending continuous BTKi monotherapy for frail patients and venetoclax-based combinations with either a BTKi (acalabrutinib, ibrutinib) or obinutuzumab for fit patients, some emphasized the overall suitability for targeted agents regardless of a traditional fitness assessment, focusing instead on specific comorbidities that might impact tolerability (e.g., cardiac or renal conditions)... This expert panel's insights address the evolving CLL treatment landscape and variable access to novel targeted therapies across LATAM, MEA, APAC, and Russia. It emphasizes that..."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Nephrology • IGH • TP53

CD5-positive lymphoproliferative disorders with atypical phenotypes are associated with inferior overall survival compared to typical-phenotype chronic lymphocytic leukaemia when treated with targeted agents. (ASH 2025) - "Chemotherapy (CT) or chemoimmunotherapy (CIT) was the first line treatment in 15 (58%) and targeted treatment (TT) in 11 (42%) including bendamustine + rituximab in 6 (23%), fludarabine + cyclophosphamide + rituximab in 3 (11.5%), dexamethasone+ cyclophosphamide+ rituximab in 2 (7.7%), chlorambucil in 3 (11.5%), rituximab alone in 1 (3.8%), acalabrutinib in 6 (23%), ibrutinib in 2 (7.7%), Zanubrutinib + venetoclax (clinical trial) in1 (3.8%) and venetoclax + obinutuzumab in 2 (7.7%). Massive splenomegaly is a major feature in patients with CD5+LPD with atypical phenotype. These patients have an inferior OS outcome when treated with TT compared to CLL patients with typical phenotype."

Clinical • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Mantle Cell Lymphoma • CCND1 • CD5

Evaluation of response assessment in chronic lymphocytic leukaemia using measurable residual disease by flow cytometry: Prospective observational study. (ASH 2025) - "Treatments included Acalabrutinib (37.9 %), Bendamustine plus Rituximab (34.5%), Ibrutinib plus Rituximab (17.2%), and single cases of Venetoclax plus Rituximab, R-CHOP, and Mini R-CHOP plus Acalabrutinib. The study is limited by a small sample size for statistical analysis and a shorter follow-up period. Overcoming these limitations would give an answer for the accurate estimation of response to therapy in CLL for future response-guided therapy."

Clinical • IO biomarker • Observational data • Residual disease • Aplastic Anemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukemia • Lymphoma • Neutropenia • Richter's Syndrome • Thrombocytopenia • IGH • NOTCH1 • TP53

Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement (ASH 2025) - "The population was further divided into two groups, those who received BTKi monotherapy (ibrutinib, zanubrutinib, acalabrutinib) and those who received fixed duration BTKi and venetoclax combination (IV). This real-world study suggests that BTKi monotherapy is non-inferior to fixed-duration BTKi and venetoclax combination therapy in terms of 2-year OS for treatment-naive B-CLL patients without TP53 mutations or IGHV gene rearrangement. We noted no statistically significant difference in the safety profiles of BTKi monotherapy and fixed-duration IV combination therapy."

Clinical • IO biomarker • Monotherapy • Real-world • Real-world evidence • Atherosclerosis • Atrial Fibrillation • Chronic Kidney Disease • Chronic Lymphocytic Leukemia • Chronic Obstructive Pulmonary Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Dyslipidemia • Fibrosis • Genetic Disorders • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Hypertension • Immunology • Infectious Disease • Leukemia • Liver Cirrhosis • Metabolic Disorders • Neutropenia • Obesity • Peripheral Arterial Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • Vascular Neurology • BCL2 • IGH • TP53

Consensus on optimal use of fixed-duration BTK inhibitor and venetoclax therapy in CLL: A delphi study comparing human expertise and AI methodologies (ASH 2025) - "- Venetoclax plus first-generation BTKi (ibrutinib) FD combinations may not be recommended for elderly patients over 70 years who are unfit, regardless of the specific comorbidity. This consensus underscores the critical importance of adopting a personalized approach to optimize the selection of BTKis within venetoclax-based FD therapies. Specifically, for elderly patients—regardless of the presence of cardiovascular comorbidities—second-generation BTKis, such as acalabrutinib, should be prioritized in venetoclax-based FD regimens. Our study is pioneering in its comparative analysis of Delphi-derived expert consensus and responses generated by ChatGPT-4."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Nephrology • IGH • TP53

Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis (ASH 2025) - "BTK inhibitors used in the studies included ibrutinib (67%, n = 775), acalabrutinib (31%, n = 363), and pirtobrutinib (2%, n = 25). Anti-CD 20 antibody was added in 188 patients, Obinutuzumab in 163 (87%), and Rituximab in 25 (13%) patients... The fixed-duration combination of BTK inhibitors and venetoclax shows very promising response rates compared to either of these agents as monotherapy. This necessitates the continuation of high-quality trials to consolidate these findings."

IO biomarker • Retrospective data • Review • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Risk of second primary malignancies in patients with chronic lymphocytic leukemia treated with zanubrutinib and acalabrutinib: A real-world data analysis (ASH 2025) - "This study showed that zanubrutinib had a lower risk of some SPM, including basal cell carcinoma, diffuse large B-cell lymphoma, and lung cancer, than compared to acalabrutinib. For other malignancies, the incidence rate was relatively comparable between both groups, although both groups experienced higher SPM than incidence rate in the general population. However, the shorter follow-up for the zanubrutinib cohort and the retrospective nature of the analysis are the limitations of this study."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Basal Cell Carcinoma • Bladder Cancer • Breast Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Genetic Disorders • Genito-urinary Cancer • Hematological Malignancies • Hodgkin Lymphoma • Kidney Cancer • Leukemia • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Oncology • Prostate Cancer • Renal Cell Carcinoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Treatment with acalabrutinib in IGHV mutated setting and presence of splenomegaly are the main predictors of faster lymphocyte count decrease in CLL during monotherapy with cbtki (ASH 2025) - "Currently, all cBTKi available in clinical practice can be used in the first line of CLL therapy, based on the results of the phase III clinical trials RESONATE-2, ELEVATE-TN and SEQUOIA, which demonstrated the superiority of Ibrutinib, Acalabrutinib and Zanubrutinib, respectively, over chemotherapy/chemoimmunotherapy in terms of progression-free survival (PFS). In conclusion, differences in ALC modification over time seem to correlate to two factors: the presence of splenomegaly before starting treatment and having mutated IGHV status, the latter during therapy with Acalabrutinib. These evidences could have an important impact in the era of oral combination therapy, considering the role of BTKi as "demarginalizing agents" able to expose neoplastic lymphocytes to the pro-apoptotic action of BCL2 inhibitors in the peripheral blood."

IO biomarker • Lymphopenia • Monotherapy • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • IGH • TP53

Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison (ASH 2025) - "The study highlights a more favorable safety profile for zanubrutinib compared to acalabrutinib, with significant differences in fatal hemorrhage, infections, cytopenias, and cardiotoxicity. Safety alone is not enough to inform treatment decisions and it is critical to consider differences in efficacy, since a safer drug that is less effective is arguably not in the best interest of patients. A network meta-analysis provided further insight, suggesting that zanubrutinib was significantly associated with lower rates of disease progression or death when compared to acalabrutinib, with a favorable trend toward being better for overall survival despite this being non-statistically significant due to the confidence intervals."

Adverse events • Clinical • Real-world • Real-world evidence • Atrial Fibrillation • Candidiasis • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Liver Failure • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

The clinical trials landscape in chronic lymphocytic leukemia: A systematic review of control arm adequacy (ASH 2025) - "The Alliance A041202 and CLL14 trials demonstrated substantial progression-free survival (PFS) benefits of BTKi monotherapy and fixed-duration venetoclax plus obinutuzumab (Ven/Obi), respectively, establishing them as standard first-line treatments...Six trials (42.8%) employed substandard control arms, all utilizing a combination of chemoimmunotherapy: fludarabine/cytarabine/rituximab or bendamustine/rituximab (n=4) or chlorambucil and rituximab (n=2)...Notably, 2 of the BTKi trials utilized ibrutinib rather than next-generation BTKis, such as acalabrutinib or zanubrutinib... Of all modern phase III trials for treatment-naive CLL, nearly half did not utilize control arms that align with the current SOC in the US or EU, risking inflated estimates of the efficacy of their experimental therapies and compromising the external validity of their results. However, although the small sample size limited statistical analysis, we found that the majority of these trials were..."

Clinical • Review • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials (ASH 2025) - "Comparisons were drawn between ven-based regimens including doublets [Ven+Obinutuzumab (Obi), Ven+Ibrutinib (Ibr), Ven+Acalabrutinib (Acala)] and triplets (BTKi + Ven + Obi) and CIT comparators such as chlorambucil+Obi or fludarabine (Flu)-based combinations...Flu cyclophosphamide rituximab/bendamustine rituximab N=519, ORR, PFS 1 year, and PFS 2 years were given as 88% (CI 56-98%), 91% ( CI 86-94%), and 80% (CI 77-84%), respectively... Ven+Obi consistently showed superior PFS and ORR compared to CIT, positioning it as a frontline standard for time-limited therapy. While the Ven+Ibr combination offered similar durability, it introduced higher cardiovascular toxicity, requiring patient-specific consideration. The addition of a third agent did not yield meaningful clinical benefit in PFS but increased myelosuppression, underscoring the need for regimen personalization."

Retrospective data • Review • Atrial Fibrillation • Chronic Lymphocytic Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Neutropenia

Oncogeriatric assessment of patients with chronic lymphatic leukaemia over 65 years old undergoing target therapies: A pilot study conducted at the fondazione policlinico gemelli. (ASH 2025) - "Treatments included ibrutinib (6), acalabrutinib (13), zanubrutinib (5), venetoclax (4), venetoclax - obinutuzumab (2), and venetoclax - rituximab (2). During the study period, 39 CLL pts were enrolled (28 males and 11 females), with a median age of 75 years (70-80). Concerning biological features, IGHV was unmutated in 16/26 (60%) pts. Del17 was present in 3/28 (11%)."

Clinical • IO biomarker • Atrial Fibrillation • Cardiomyopathy • Chronic Lymphocytic Leukemia • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Malignancies • Hypertension • Leukemia • Metabolic Disorders • Renal Disease • TP53

Survival trends in chronic lymphocytic leukemia before and after BTK inhibitors era: A SEER database analysis (ASH 2025) - "Bruton kinase inhibitors (BTKi) such as Ibrutinib, Acalabrutinib and Zanubrutinib have revolutionized the treatment of CLL by irreversibly binding to BTK, an enzyme crucial for B-cell signaling pathways, and preventing the survival and proliferation of malignant B-cells. Given the indolent nature of CLL, patients who received chemotherapy showed lower median survival—possibly reflecting treatment-related toxicity. Younger patients demonstrated better outcomes, while the geriatric population had poorer survival, likely due to comorbidities. The significantly higher incidence in the White population suggests potential genetic or environmental factors that warrant further investigation."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel (ASH 2025) - " Using the Mayo Clinic CLL Database and the Mayo Clinic CLL Tissue Bank, we identified 47 patients with RR CLL, all of whom experienced disease progressionon a BTKi (35 ibrutinib +/- CD20 antibody, 10 acalabrutinib +/- CD20 antibody, 2 other)...We also observed that RR CLL cohort exhibited significantly increased drug resistance to most of the tested drugs in the presence of BMSCs with corresponding increases in IC50s (with vs. without BMSCs, fold-change respectively): LP-118 3.92-fold, venetoclax 1.98-fold, carfilzomib 2.58-fold, TP-0903 1.65-fold, panobinostat 204.23-fold, TCIP1 1.91-fold, crenolanib 1.31-fold, idasanutlin 1.69-fold, belinostat 6.14-fold, LP-168 1.29-fold, eprenetapopt 3.44-fold and GTE 1.08-fold (11 out of 12 with p -values <0.05 except for GTE which was not significant, Mann-Whitney U test)... Our results highlight the spectrum of currently available drugs that show promise for therapeutic use in patients with RR CLL who experience disease..."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • AXL • BCL2 • STAT6 • TP53

BTK inhibition drives mobilization and compartmental shifts of CLL subclones (ASH 2025) - P2 | "Whole exome sequencing (WES), and bulk RNA sequencing was performed samples from 65 patients treated with either ibrutinib (n=35; baseline and 24h or 72h after first dose) or acalabrutinib (n=30; baseline and after 96±20h of treatment). Many subclones shifted compartment bias on treatment, but not all LN resident subclones appeared to be mobilized. A deeper understanding of compartmentalization is critical for tracking clonal evolution and understanding treatment resistance."

Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • ATM • NOTCH1 • SF3B1 • TP53

Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience (ASH 2025) - " We reviewed all patients treated at our institution with either acalabrutinib or zanubrutinib (BTKi) +/- maintenance rituximab who had therapy initiated by July 10, 2024. Second-generation BTKi with and without rituximab appear safe and effective frontline therapy for MCL regardless of patient age. We also observed excellent BTKi outcomes in younger patients comparable to standard-of-care chemotherapy. Limitations include a higher proportion of patients in the frontline chemotherapy group with blastoid MCL as well as relatively short follow-up in the BTKi cohort."

Clinical • Bone Marrow Transplantation • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Nephrology • Neutropenia • Pneumonia • Respiratory Diseases • TP53